Errata

The June 1, 2017, article by Martinelli, et al, entitled “Complete Hematologic and Molecular Response in Adult Patients With Relapsed/Refractory Philadelphia Chromosome–Positive B-Precursor Acute Lymphoblastic Leukemia Following Treatment With Blinatumomab: Results From a Phase II, Single-Arm, Multicenter Study,” (J Clin Oncol 35:1795-1802, 2017), contained an error.

In the legend of table 2, last key, the “of” should be replaced with $\geq$. The sentence should have read as, “Complete

MRD response was defined as no detectable PCR amplification of *BCR-ABL1* genes (sensitivity $\geq 10^{-5}$) as assessed by a central laboratory.”

The online version has been corrected in departure from the print. The authors apologize for the error.

DOI: <https://doi.org/10.1200/JCO.2017.74.7550>; published August 10, 2017

The January 1, 2012, article by Chawla et al, entitled “Phase II Study of the Mammalian Target of Rapamycin Inhibitor Ridaforolimus in Patients With Advanced Bone and Soft Tissue Sarcomas,” (*Journal of Clinical Oncology* 30:78-84), was published with an error of omission.

The article should have included the clinicaltrials.gov registration number (NCT number).

The line just above the Author’s Disclosures was given as: Clinical trial information can be found for the following: NCT00112372.

Instead, the line just above the Author’s Disclosures section should read: Clinical trial information can be found for the following: NCT00112372 **and NCT00093080.**

The online version has been corrected in departure from the print. Production regrets the omission.

DOI: <https://doi.org/10.1200/JCO.2017.72.6828>; published August 10, 2017

The May 1, 2017, article by Rosenthal et al, entitled “Evidence of Stage Shift in Women Diagnosed With Ovarian Cancer During Phase II of the United Kingdom Familial Ovarian Cancer Screening Study” (J Clin Oncol 35:1411-1420, 2017), was published with an error.

The second paragraph of the Results stated: “Follow-up until date of last cancer registration (or death, if this occurred previously) was possible for 4,336 women (99.7%). Twelve women emigrated, so they could not be observed via registries

for the entire period. Median follow-up beyond last screen/withdrawal was 4.8 years (range, 0.1 to 8.7 years).”

This should have stated “**Follow-up was possible for 4,046 women (93.1%). Median follow-up beyond last screen/withdrawal was 4.7 years (range, 0 to 8.7 years).**”

The online version has been corrected in departure from the print. The authors apologize for the error.

DOI: <https://doi.org/10.1200/JCO.2017.74.8830>; published August 10, 2017